Renewable Energy

UniQure NV weighs options including sale -Bloomberg

Gene therapy company UniQure NV is exploring options including a sale amid interest from other pharmaceutical companies looking to expand in gene therapy, Bloomberg reported on Sunday citing people with knowledge of the matter.

June 16 (Reuters) - Gene therapy company UniQure NV QURE.O is exploring options including a sale amid interest from other pharmaceutical companies looking to expand in gene therapy, Bloomberg reported on Sunday citing people with knowledge of the matter.

No final decisions have been made, and there is no certainty the deliberations will lead to a transaction, Bloomberg said citing sources.

Many pharmaceutical firms have been pursuing gene-therapy companies that promise to treat rare, debilitating diseases by correcting DNA flaws.

The biotechnology company is working with advisers as it weighs options, the report added.

UniQure was not immediately available for a comment.

(Reporting by Rishika Chatterjee in Bengaluru Editing by Nick Zieminski)

((Rishika.Chatterjee@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 99 7277 8938; Reuters Messaging: rishika.chatterjee.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More